Table 1 Patient characteristics at baseline
Characteristics | Patients (N = 24) |
|---|---|
Age | |
Median (Range) | 67.5 (41–89) |
Sex | |
Female | 4 (16.7%) |
Male | 20 (83.3%) |
PS | |
Tumor-related PS 2 | 22 (91.7%) |
Non-tumor-related PS 2 | 2 (8.3%) |
Primary site | |
Gastric | 24 (100.0%) |
Gastroesophageal junction | 0 (0%) |
Previous gastrectomy | |
Yes | 7 (29.2%) |
No | 17 (70.8%) |
Previous adjuvant chemotherapy | |
Yes | 4 (16.7%) |
No | 20 (83.3%) |
Number of metastatic sites | |
1 | 9 (37.5%) |
≥2 | 15 (62.5%) |
Metastatic site | |
Distant lymph node | 20 (83.3%) |
Liver | 11 (45.8%) |
Lung | 6 (25.0%) |
Peritoneum | 3 (12.5%) |
Other | 4 (16.7%) |
MMR status | |
dMMR | 0 (0%) |
pMMR | 24 (100%) |
ERBB2 amplification | |
Yes | 0 (3.3%) |
No | 24 (96.7%) |
PD-L1 expression | |
CPS <1 | 11 (45.8%) |
CPS ≥1 | 10 (41.7%) |
Unknown | 3 (12.5%) |
TMB (Mutation/Mb), median (Range) | 8.38 (3.35–27.4) |
